Who was Barbara Mitchell?
  1. Author Library
  2. Author Library

Author Library

Canada does not need a modern ‘Marshall Plan’ after COVID
By Steven Globerman, Jake Fuss | April 22, 2020
Modern Monetary Theory, Part 3: MMT and inflation
By Steven Globerman | April 14, 2020
Alberta should fund AER through general tax revenue
By Steven Globerman, Jairo Yunis | March 31, 2020
Modern Monetary Theory, Part 2: Will MMT hold down taxes?
By Steven Globerman | March 30, 2020
Modern Monetary Theory, Part 1: What is it and why is it gaining currency in these volatile times?
By Steven Globerman | March 23, 2020
Kenney government should reform Alberta energy regulations
By Steven Globerman, Jairo Yunis | March 19, 2020
Canada must rethink restrictions on private health insurance—for the sake of patients
By Steven Globerman | February 4, 2020
Other universal health-care countries allow private health insurance—and have shorter wait times
By Mackenzie Moir, Bacchus Barua, Steven Globerman | January 31, 2020
Understanding Universal Health Care Reform Options: Private Insurance
By Steven Globerman | January 21, 2020
Congressional voting on USMCA underscores influence of interest groups
By Steven Globerman | January 10, 2020
Canadian cheers over pending USMCA may be short-lived
By Steven Globerman | December 11, 2019
Trump tariff threat highlights fundamental change in Canada-U.S. relations
By Steven Globerman | December 9, 2019
Property tax rates much higher for businesses than residents—which can cause serious problems
By Josef Filipowicz, Steven Globerman | November 23, 2019
Reforming Alberta energy regulation—here’s how
By Steven Globerman, Jairo Yunis | November 23, 2019
Evaluating Alberta's Energy Regulator
By Steven Globerman, Jairo Yunis | November 21, 2019
Property tax imbalance erodes political accountability, discourages business investment
By Josef Filipowicz, Steven Globerman | October 31, 2019
Who Bears the Burden of Property Taxes in Canada’s Largest Metropolitan Areas?
By Josef Filipowicz, Steven Globerman | October 17, 2019
The Costs of Slow Economic Growth: Collected Essays
By Steven Globerman | October 10, 2019
Private health insurance, not government bureaucracy, spurs health-care innovation
By Steven Globerman | September 13, 2019
Health care cannot modernize unless health policy changes first
By Bacchus Barua, Steven Globerman | August 20, 2019
Canada can’t escape Trump administration’s war on trade
By Steven Globerman | August 6, 2019
Federal government should give greater weight to education credentials to attract ‘elite’ immigrants
By Steven Globerman | July 26, 2019
Highly Educated Immigrants: Economic Contributions and Implications for Public Policy
By Steven Globerman | July 23, 2019
Artificial Intelligence will kill jobs—and create them
By Steven Globerman | July 12, 2019
Dramatic drop in capital expenditures threatens Canada’s economic prosperity
By Steven Globerman | July 12, 2019
Technology, Automation, and Employment: Will this Time be Different?
By Steven Globerman | July 9, 2019
Private Sector Capital Expenditures in Canada: An Industry-Level Analysis
By Steven Globerman, Joel Emes | July 3, 2019
Trump’s tariff tactics will end badly for U.S.—and Canada
By Steven Globerman | June 4, 2019
Foreign investment in Canada—nothing to celebrate
By Steven Globerman | May 24, 2019
Canada’s upstream oil and gas sector—from the outpatient clinic to intensive care
By Steven Globerman, Joel Emes | May 16, 2019
Slowdown of world economic growth would likely reduce demand for Canadian resource exports
By Steven Globerman | May 14, 2019
Investment in the Canadian and U.S. Oil and Gas Sectors: A Tale of Diverging Fortunes
By Steven Globerman, Joel Emes | May 7, 2019
Americans want prescription drugs from Canada
By Steven Globerman | April 18, 2019
Paying companies to stay—bad idea
By Steven Globerman | March 27, 2019
Canadian Foreign Direct Investment: Recent Patterns and Interpretation
By Steven Globerman | March 21, 2019
Private sector helping address physician scarcity in the U.S.
By Steven Globerman, Bacchus Barua | March 13, 2019
Trudeau government's drug-pricing plan may limit access to new life-improving medicines
By Bacchus Barua, Steven Globerman | February 21, 2019
'Tax the rich' movement in the U.S. may benefit Canada
By Steven Globerman | February 11, 2019
Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective
By Steven Globerman, Bacchus Barua | January 24, 2019
Canadian policymakers should learn from Trump's supply-side success
By Steven Globerman | January 17, 2019
Despite decades of government subsidies, Canadian innovation has waned
By Steven Globerman | January 15, 2019
Innovation in Canada: An Assessment of Recent Experience
By Steven Globerman, Joel Emes | January 15, 2019
Canada's free ride on U.S. drug development may end soon
By Steven Globerman, Bacchus Barua | December 11, 2018
Regulatory reform in Canada should focus on streamlining deregulation
By Steven Globerman | November 27, 2018
NAFTA renegotiations—a missed opportunity for Canada
By Steven Globerman, Gary Hufbauer | November 19, 2018
The Flight of Capital From Canada
By Niels Veldhuis, Jason Clemens, Milagros Palacios, Steven Globerman | November 19, 2018
U.S. market won't save Canada's oil sector
By Steven Globerman | November 16, 2018
A split Congress may increase uncertainty surrounding Canada’s trade environment
By Steven Globerman | November 8, 2018
The United States–Mexico–Canada Agreement: Overview and Outlook
By Gary Hufbauer, Steven Globerman | November 1, 2018
Wake up—Canada has a business investment crisis
By Steven Globerman | October 24, 2018